NCT00937378已完成3 期
A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia (Non PK Study)
Serenity Pharmaceuticals, Inc.1 个研究点 分布在 1 个国家目标入组 326 人开始时间: 2009年6月最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 326
- 试验地点
- 1
- 主要终点
- Change in Mean Number of Nocturic Episodes/Night
研究概览
简要总结
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female 50 years or older
- •Nocturia of 6 or more months duration averaging 2 episodes or more per night
排除标准
- •Diabetes Insipidus, Renal Insufficiency, Hepatic Insufficiency
- •Incontinence
- •Illness requiring steroids
- •Current or past urologic malignancy
- •Nephrotic Syndrome
- •Unexplained pelvic masses
- •Urinary bladder neurological dysfunction
- •Urinary bladder surgery or radiotherapy
- •Sleep Apnea
- •Pregnant or breast feeding
研究组 & 干预措施
SER120
Experimental
干预措施: SER120 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Mean Number of Nocturic Episodes/Night
时间窗: 7 weeks
Change was calculated as the mean number of nocturic episodes per night between baseline and Week 7
Percent of Participants With at Least 50% Decrease in Mean Nocturic Episodes Per Night
时间窗: 7 weeks
Percent of participants achieving at least 50% reduction in nocturic episodes during the last week of treatment compared to baseline
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Treatment of Patients With NocturiaNocturiaNCT00937859Serenity Pharmaceuticals, Inc.301
已完成
3 期
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4NocturiaNCT01900704Serenity Pharmaceuticals, Inc.810
已完成
2 期
Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone SecretionSyndrome of Inappropriate ADH (SIADH) SecretionHyponatremiaNCT00032734Sanofi35
已完成
4 期
Efficacy of Suvorexant to Treat Insomnia Related to Bipolar DisorderInsomniaBipolar DisorderNCT02527564Stanford University61
已完成
不适用
A 12-weeks Study to Evaluate Sulforaphane in Treatment of Autism Spectrum DisorderAutism Spectrum DisorderNCT02879110Central South University110